AQST Q1 2023 Earnings — Aquestive Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

AQSTAquestive Therapeutics, Inc.

$431M

Q1 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$11M-9.3% YoY

Gross Profit

$6M57.5% margin

Operating Income

-$5M-41.4% margin

Net Income

$8M72.5% margin

EPS (Diluted)

$0.26

QoQ Revenue Growth

+4.2%

Cash Flow

Operating Cash Flow

$9M

Free Cash Flow

$9M

Stock-Based Comp.

$344,000

Balance Sheet

Total Assets

$61M

Total Liabilities

$171M

Stockholders' Equity

-$109M

Cash & Equivalents

$27M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$11M	$12M	-9.3%
Gross Profit	$6M	$8M	-20.6%
Operating Income	-$5M	-$10M	+52.7%
Net Income	$8M	-$13M	+161.0%

Revenue Segments

Manufacture and Supply Revenue

$10M88%

License and Royalty Revenue

$919,0008%

Co-Development and Research Fees

$453,0004%

Geographic Segments

UNITED STATES

$8M73%

Non-US

$3M27%